Earnings Releases·Nov 9, 2026, 7:39 AM ET

ImmunityBio — Q3 2026 Earnings Summary

Net product revenue surged 53% year-over-year to $48.7 million in Q3 2026 and 92% to $143.6 million for the first nine months, driven by ANKTIVA sales, while total revenue reached $48.8 million for the quarter and $144.3 million for the nine-month period.
Net loss attributable to common stockholders widened significantly to $184.6 million for Q3 2026 (vs. $67.3 million in Q3 2025) and $1.0 billion for the first nine months (vs. $289.5 million), largely due to non-cash fair value changes in derivative liabilities and a one-time convertible note receivable write-off.
ANKTIVA received FDA approval on October 14, 2026, for BCG-unresponsive NMIBC with papillary-only tumors, bringing total regulatory approvals to six jurisdictions across 35 countries, with an sBLA submission for BCG-naïve NMIBC planned for Q4 2026.
The company's liquidity position strengthened to $334.3 million in cash and marketable securities as of September 30, 2026, though total liabilities rose to $1.75 billion and operating cash flow for the first nine months was $(217.2) million.
Management anticipates long-term growth through global commercial expansion, real-world evidence studies, and clinical advancements in metastatic non-small cell lung cancer, GBM, and hematologic malignancies.